Solitary fibrous tumor

Brian Davanzo, Robert Emerson, Megan Lisy, Leonidas Koniaris, Joshua K. Kays

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Solitary fibrous tumor (SFT) is a rare tumor of mesenchymal origin that account for less than 2% of all soft tissue masses. Initially identified in the pleura, SFT has been identified in multiple anatomic locations and can arise anywhere in the body. The varying histologic features along with non-specific means of identification have led SFT to be associated with several different names. Over the last several decades, sustained advances through research and technology have led to more reliable methods for differentiating this distinct soft tissue tumor. Advances specifically in immunohistochemistry and molecular diagnostics have identified CD34 as the most consistent marker in SFT, however even this lacks specificity to conclusively narrow down the broad differential for exact identification. More recently the discovery of the NAB2-STAT6 fusion gene has led to more precise diagnosis of SFT. Like many other soft tissue tumors, surgical management is the mainstay of treatment for SFT with emphasis on obtaining tumor-negative margins. Radiation therapy and chemotherapy regimens have not demonstrated global effectiveness, and thus no standardized treatments have been identified. Given the rarity of SFT and current supportive evidence for therapies, management should be focused on tumor extirpation. Nonetheless, individualized therapy, determined within a multidisciplinary setting should be considered.

Original languageEnglish (US)
Article number94
JournalTranslational Gastroenterology and Hepatology
Volume3
Issue numberNovember
DOIs
StatePublished - Nov 1 2018

Fingerprint

Solitary Fibrous Tumors
Neoplasms
Pleural Solitary Fibrous Tumor
Molecular Pathology
Gene Fusion
Therapeutics
Names
Radiotherapy
Immunohistochemistry
Technology
Drug Therapy
Research

Keywords

  • Hemangiopericytoma
  • Sarcoma
  • Solitary fibrous tumors (SFT)

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Solitary fibrous tumor. / Davanzo, Brian; Emerson, Robert; Lisy, Megan; Koniaris, Leonidas; Kays, Joshua K.

In: Translational Gastroenterology and Hepatology, Vol. 3, No. November, 94, 01.11.2018.

Research output: Contribution to journalReview article

Davanzo, Brian ; Emerson, Robert ; Lisy, Megan ; Koniaris, Leonidas ; Kays, Joshua K. / Solitary fibrous tumor. In: Translational Gastroenterology and Hepatology. 2018 ; Vol. 3, No. November.
@article{7c62c1c043d54c75b1b10b5bbab539ed,
title = "Solitary fibrous tumor",
abstract = "Solitary fibrous tumor (SFT) is a rare tumor of mesenchymal origin that account for less than 2{\%} of all soft tissue masses. Initially identified in the pleura, SFT has been identified in multiple anatomic locations and can arise anywhere in the body. The varying histologic features along with non-specific means of identification have led SFT to be associated with several different names. Over the last several decades, sustained advances through research and technology have led to more reliable methods for differentiating this distinct soft tissue tumor. Advances specifically in immunohistochemistry and molecular diagnostics have identified CD34 as the most consistent marker in SFT, however even this lacks specificity to conclusively narrow down the broad differential for exact identification. More recently the discovery of the NAB2-STAT6 fusion gene has led to more precise diagnosis of SFT. Like many other soft tissue tumors, surgical management is the mainstay of treatment for SFT with emphasis on obtaining tumor-negative margins. Radiation therapy and chemotherapy regimens have not demonstrated global effectiveness, and thus no standardized treatments have been identified. Given the rarity of SFT and current supportive evidence for therapies, management should be focused on tumor extirpation. Nonetheless, individualized therapy, determined within a multidisciplinary setting should be considered.",
keywords = "Hemangiopericytoma, Sarcoma, Solitary fibrous tumors (SFT)",
author = "Brian Davanzo and Robert Emerson and Megan Lisy and Leonidas Koniaris and Kays, {Joshua K.}",
year = "2018",
month = "11",
day = "1",
doi = "10.21037/tgh.2018.11.02",
language = "English (US)",
volume = "3",
journal = "Translational Gastroenterology and Hepatology",
issn = "2224-476X",
publisher = "AME Publishing Company",
number = "November",

}

TY - JOUR

T1 - Solitary fibrous tumor

AU - Davanzo, Brian

AU - Emerson, Robert

AU - Lisy, Megan

AU - Koniaris, Leonidas

AU - Kays, Joshua K.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Solitary fibrous tumor (SFT) is a rare tumor of mesenchymal origin that account for less than 2% of all soft tissue masses. Initially identified in the pleura, SFT has been identified in multiple anatomic locations and can arise anywhere in the body. The varying histologic features along with non-specific means of identification have led SFT to be associated with several different names. Over the last several decades, sustained advances through research and technology have led to more reliable methods for differentiating this distinct soft tissue tumor. Advances specifically in immunohistochemistry and molecular diagnostics have identified CD34 as the most consistent marker in SFT, however even this lacks specificity to conclusively narrow down the broad differential for exact identification. More recently the discovery of the NAB2-STAT6 fusion gene has led to more precise diagnosis of SFT. Like many other soft tissue tumors, surgical management is the mainstay of treatment for SFT with emphasis on obtaining tumor-negative margins. Radiation therapy and chemotherapy regimens have not demonstrated global effectiveness, and thus no standardized treatments have been identified. Given the rarity of SFT and current supportive evidence for therapies, management should be focused on tumor extirpation. Nonetheless, individualized therapy, determined within a multidisciplinary setting should be considered.

AB - Solitary fibrous tumor (SFT) is a rare tumor of mesenchymal origin that account for less than 2% of all soft tissue masses. Initially identified in the pleura, SFT has been identified in multiple anatomic locations and can arise anywhere in the body. The varying histologic features along with non-specific means of identification have led SFT to be associated with several different names. Over the last several decades, sustained advances through research and technology have led to more reliable methods for differentiating this distinct soft tissue tumor. Advances specifically in immunohistochemistry and molecular diagnostics have identified CD34 as the most consistent marker in SFT, however even this lacks specificity to conclusively narrow down the broad differential for exact identification. More recently the discovery of the NAB2-STAT6 fusion gene has led to more precise diagnosis of SFT. Like many other soft tissue tumors, surgical management is the mainstay of treatment for SFT with emphasis on obtaining tumor-negative margins. Radiation therapy and chemotherapy regimens have not demonstrated global effectiveness, and thus no standardized treatments have been identified. Given the rarity of SFT and current supportive evidence for therapies, management should be focused on tumor extirpation. Nonetheless, individualized therapy, determined within a multidisciplinary setting should be considered.

KW - Hemangiopericytoma

KW - Sarcoma

KW - Solitary fibrous tumors (SFT)

UR - http://www.scopus.com/inward/record.url?scp=85057582277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057582277&partnerID=8YFLogxK

U2 - 10.21037/tgh.2018.11.02

DO - 10.21037/tgh.2018.11.02

M3 - Review article

AN - SCOPUS:85057582277

VL - 3

JO - Translational Gastroenterology and Hepatology

JF - Translational Gastroenterology and Hepatology

SN - 2224-476X

IS - November

M1 - 94

ER -